ArticlePediatric nephrology (Berlin, Germany)2018
Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
Article in Pediatric nephrology (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Masked hypertension and non-dipping blood pressure profiles in pediatric survivors of acute kidney injury: a systematic review and meta-analysis.Journal of human hypertension · 2026Pooled it
- Long-term cisplatin nephrotoxicity after childhood cancer: a systematic review and meta-analysis.Pediatric nephrology (Berlin, Germany) · 2024Pooled it
- Acute kidney injury during treatment of pediatric brain tumors: a retrospective analysis of survivors.Pediatric research · 2026Article
- Hypomagnesemia: A Clinical and Nutritional Update.Current nutrition reports · 2026Review
- Incidence of and risk factors for chronic kidney disease in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026Article
- Urinary TIMP-2*IGFBP-7 to diagnose acute kidney injury in children receiving cisplatin.Pediatric nephrology (Berlin, Germany) · 2024Article
- PTEN in kidney diseases: a potential therapeutic target in preventing AKI-to-CKD transition.Frontiers in medicine · 2024Review
- Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.International journal of clinical oncology · 2023Review
- Chronic kidney disease in children: an update.Clinical kidney journal · 2023Review
- Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study.Pediatric nephrology (Berlin, Germany) · 2023Observational
- Long-Term Kidney and Cardiovascular Complications in Pediatric Cancer Survivors.The Journal of pediatrics · 2023Article
- Roles of DNA damage in renal tubular epithelial cells injury.Frontiers in physiology · 2023Review
- Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment.Journal of cardiovascular pharmacology · 2022Review
- Pharmacological inhibitors of autophagy have opposite effects in acute and chronic cisplatin-induced kidney injury.American journal of physiology. Renal physiology · 2022Article
- Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.Pediatric nephrology (Berlin, Germany) · 2022Article
- Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.Kidney360 · 2022Article
- KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors: Description of Clinical Research Protocol of the KINDEST-CCS Study.Canadian journal of kidney health and disease · 2022Article
- Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.European journal of cancer (Oxford, England : 1990) · 2021Article
- An overview of diagnosis and management of drug-induced hypomagnesemia.Pharmacology research & perspectives · 2021Review
- Childhood risk factors for adulthood chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h ambulatory BP monitoring (ABPM) in this population. We aimed to describe chemotherapy-associated acute kidney injury (AKI) and late kidney outcomes using standardized definitions.
methodsThis was a single-center longitudinal pilot study of 23 children who participated in a previous study during cisplatin, carboplatin, or ifosfamide treatment. Medical charts were reviewed retrospectively. Available patients were approached for a study visit for blood and urine collection, BP measurement, and ABPM. AKI is defined by serum creatinine (SCr) rise (Kidney Disease: Improving Global Outcomes definition [SCr-AKI]). Electrolyte-AKI is defined by hypokalemia, hypophosphatemia, or hypomagnesemia. Chronic kidney disease (CKD) is defined by estimated glomerular filtration rate < 90 mL/min/1.73 m
resultsMedian age at chemotherapy start was 8.3 years; 9/23 (39%) were boys. Fourteen out of 23 (61%) patients had SCr-AKI during therapy; all developed electrolyte-AKI. Median 5.7 years post-chemotherapy, 7/22 (32%) had CKD, 11/23 (48%) had electrolyte-CKD, and 2/20 (10%) had hypertension. Fifteen out of 23 patients (65%) had either CKD, electrolyte-CKD, or hypertension. In ten patients available for a study visit (median 4.9 years post-chemotherapy), 1/10 (10%) had hypertension by ABPM; none had masked or white coat hypertension. All ten had at least one kidney abnormality (CKD, electrolyte-CKD, office pre-hypertension, or abnormal ABPM).
conclusionsUsing standardized outcome definitions, children treated with cisplatin, carboplatin, or ifosfamide have a high prevalence of late kidney abnormalities. Research must elucidate best practice for post-cancer treatment follow-up and kidney complication treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.